Therapy Trends KOL Insight: Prostate Cancer [2018]

Maximum Purchase:
1 unit
Publication Date:
October 2018
Adding to cart… The item has been added

How will established and emerging agents reshape the prostate cancer treatment landscape?

A plethora of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key opinion leaders (KOLs) are excited about the use of next-generation hormonal therapies and personalised approaches with PARP inhibitors and PD-1/PD-L1 immunotherapies, but which therapies will stand out in an evolving and competitive landscape? Other innovative targeted agents are also in the pipeline but which segment of the market can they expect to capture?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in Therapy Trends KOL Insight: Prostate Cancer. Twelve US and European KOLs provide their candid insights on seven marketed products and twelve pipeline programmes.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • Which next-generation androgen receptor inhibitor is most favoured among experts? How are Xtandi and Zytiga currently prescribed and what drives physician preference between these agents?
  • How will Xtandi usage evolve in the future and which trials are going to have the most impact? With several Phase III studies investigating Xtandi across numerous settings, find out which studies KOLs are most optimistic about.
  • How will use of Erleada evolve over the next three to five years? Are the expected results of ongoing Phase III TITAN and ATLAS trials anticipated to have an impact?
  • How is darolutamide viewed by KOLs and does it have differentiating qualities from other agents? What could help this next-generation androgen receptor antagonist win future market share?
  • Are immunotherapies considered important in prostate cancer? Do KOLs believe that vaccine-based therapies or PD-1/PD-L1 checkpoint inhibitors hold any opportunity in prostate cancer and if so, which approaches are the most promising?
  • Do PARP inhibitors represent an important advance for the personalised treatment of prostate cancer? Find out how KOLs think Lynparza, Rubraca and talazoparib compare and if they can change treatment for biomarker-selected patient groups?
  • Which innovative mechanisms of action are KOLs most excited about? Ipatasertib, 177Lu-PSMA-617 and masitinib are all undergoing late-stage evaluation, but how do the KOLs view these agents for prostate cancer?
Request sample pages

Back to the top


“Maybe in five years, there will be more targetable drug therapies for various mutations, and biomarkers to identify the right patients for it. I think that the personalised medicine approach is going to be more predominant or prevalent in those five years.”
US Key Opinion Leader

“We'll pick up more and more and so the [non-metastatic] space will be a very small space. Because we'll detect a lot of disease early on.”
US Key Opinion Leader

“I think it will be more combination strategies. We may have PARP inhibitors, and checkpoint inhibitors coming through with the various combinations. So, we'll have a totally different landscape in maybe five years.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Xtandi (enzalutamide; Astellas/Pfizer)
  • Zytiga (abiraterone acetate; J&J)
  • Erleada (apalutamide; J&J)
  • Yonsa (micronised abiraterone acetate; Sun Pharma/Churchill Pharma)
  • Xofigo (radium-223 dichloride; Algeta/Bayer)
  • Xgeva/Prolia (denosumab; Amgen)
  • Provenge (sipuleucel-T; Sanpower Group)

Pipeline Therapies

  • darolutamide (ODM-201; Bayer/Orion)
  • PROSTVAC (rilimogene galvacirepvec/ rilimogene glafolivec; Bavarian Nordic/Bristol-Myers Squibb)
  • DCVAC/PCa (stapuldencel-T; Sotio)
  • ProstAtak (aglatimagene besadenovec; Advantagene)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Lynparza (olaparib; AstraZeneca)
  • Rubraca (rucaparib; Clovis Oncology)
  • talazoparib (Pfizer)
  • ipatasertib (Array BioPharma/Roche)
  • 177LU-PSMA-617 (Endocyte)
  • masitinib (AB Science)

KOLs interviewed

KOLs from North America

  • Dr. Tomasz M. Beer MD FACP, Professor at the Division of Hematology and Medical Oncology and Deputy Director, Oregon Health & Science University Knight Cancer Institute, Portland, OR.
  • Dr. Saby George MD FACP, Associate Professor of Oncology at the Roswell Park Cancer Institute, Buffalo, NY.
  • Dr. Michael Zelefsky MD, Vice Chair at the Department of Radiation Oncology and Clinical Research, and Chief of the Brachytherapy Service, Memorial Sloan Kettering Cancer Center, NY.
  • Dr. Andrew Armstrong MD, co-program leader of the genitourinary oncology research program at the Duke Comprehensive Cancer Center, Duke University Medical Center, NC.
  • Dr. Daniel Petrylak MD, Professor of Medicine (Medical Oncology) and of Urology at Yale University, CT.
  • Dr. James Mohler MD, Professor of Oncology at School of Medicine and Biomedical Sciences, State University of New York, NY.

KOLs from Europe

  • Dr. Chris Parker MD FRCR MRCP, Senior Lecturer and Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at the Institute of Cancer Research and the Royal Marsden, London, UK.
  • Dr. John P. Logue MB MRCP FRCR, Consultant Clinical Oncologist at The Christie hospital, Manchester, UK.
  • Dr. Stephane Oudard MD, Professor of Medical Oncology, Georges Pompidou European Hospital, Paris, France.
  • Dr Karim Fizazi MD, Head of the Department of Cancer Medicine, University of Paris, France.
  • Anonymous German KOL, Professor at a major university hospital, Germany.
  • Anonymous German KOL, Professor at a major university, Germany.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.